PracticeUpdate Conference Series European Congress of Psychiatry 2019

© EPA 2019

Contents

EPA 2019 • 6–9 April 2019 • Warsaw, Poland BY THE PRACTICEUPDATE EDITORIAL TEAM

3

10

16

3 Gut Microbiota Affect and Are Affected by Depression 4 Five Patient Characteristics Predict Recurrence of Major Depressive Disorder 5 Trazodone OAB Proves Non-Inferior to Venlafaxine XR for Major Depressive Disorder 6 Positive Emotions Following Stroke Predictive of Functional Recovery 7 Hypertension Linked With Increased Risk of Anxiety and Depression 8 Adolescent Sleep Problems Typically Precede Anxiety Symptoms

10 Baseline Depression Severity Does Not Affect Benefits of Antidepressant Therapy 11 Lurasidone Safe, Effective for Major Depressive Disorder With Mixed Features 12 Risk Profiles Can Identify Seniors’ Likelihood for Suicidal Ideation and Attempts 12 Mood Disorders With Comorbid Disease Linked With Elevated Mortality Risk in the Elderly 14 Symptom Remission May Not Equate to Functional Recovery in Depression

15 To Date, Only Hydrocortisone Shows 16 Early Antidepressant Response Not 18 Nutraceuticals Might Be Effective Adjunctive Therapy for Bipolar Disorder 19 Insomnia Associated With Reduced Health- Related Quality of Life 20 Consider Psychiatric Referrals for Patients With Unexplained Somatic Complaints Promise for Pharmacologic Prevention of PTSD Sufficiently Predictive of Later Response In Major Depression

The production and distribution of this publication is sponsored by Janssen. The provision of this information is not intended to advocate any use not covered by the Product Information. Please check that the product is approved for use and always consult the Product Information before prescribing.

1

EPA 2019 • PRACTICEUPDATE CONFERENCE SERIES